Pancreatic Cancer Research

ResearcherNational Cancer InstituteNo recent work listed

Altaf Mohammed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1058-6909; OpenAlex author ID A5043464019; NIH RePORTER profile ID 10801601. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
21
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers, 1 grant · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 18

  1. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  2. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Co-author DOI 10.1101/2021.11.29.470415↗
  3. Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention. Co-author DOI 10.1002/mc.23084↗
  4. Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170209104453↗
  5. Immunoprevention of Pancreatic Cancer. First author DOI 10.2174/0929867324666170223153509↗
  6. Pancreatic Cancer Chemoprevention: Challenges and Opportunities. Co-author DOI 10.2174/092986732522180704091601↗
  7. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras G12D/+ mice. First author DOI 10.1111/imm.12746↗
  8. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Co-author DOI 10.18632/oncotarget.22085↗
  9. Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-15-2820↗
  10. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.3499↗
  11. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.5396↗
  12. Molecular Targeted Intervention for Pancreatic Cancer. Co-author DOI 10.3390/cancers7030850↗
  13. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Co-author DOI 10.1158/1940-6207.capr-14-0176↗
  14. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. First author DOI 10.1002/ijc.28285↗
  15. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Co-author DOI 10.1593/tlo.13556↗
  16. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice. Co-author DOI 10.1593/neo.121508↗
  17. Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. Co-author DOI 10.2174/092986712801661095↗
  18. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. First author DOI 10.1007/s10555-011-9311-2↗

Grants 1

  1. Targeting cancer stem cell initiation during pancreatic cancer development R03CA181584↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chinthalapally V. Rao · 16 shared papers, 2011–2019 · strength 1.05
  2. Naveena B. Janakiram · 10 shared papers, 1 shared grant, 2011–2019 · strength 0.78
  3. Dafna Bar‐Sagi · 2 shared papers, 2021–2023 · strength 0.22
  4. Powel H. Brown · 2 shared papers, 2021–2023 · strength 0.22
  5. Kanchan Singh · 2 shared papers, 2021–2023 · strength 0.22
  6. Erika Yanil Faraoni · 2 shared papers, 2021–2023 · strength 0.22
  7. Vidhi Chandra · 2 shared papers, 2021–2023 · strength 0.22
  8. Curtis Jackson Wray · 2 shared papers, 2021–2023 · strength 0.22
  9. Nirav C Thosani · 2 shared papers, 2021–2023 · strength 0.22
  10. Florencia M. McAllister · 2 shared papers, 2021–2023 · strength 0.22
  11. George Van Buren · 2 shared papers, 2021–2023 · strength 0.22
  12. Jennifer M. Bailey · 2 shared papers, 2021–2023 · strength 0.22
  13. Lincoln N. Strickland · 1 shared paper, 2023 · strength 0.13
  14. Le Li · 1 shared paper, 2023 · strength 0.13
  15. Gaurav Kumar · 2 shared papers, 2015–2016 · strength 0.09
  16. Shubham Pant · 1 shared paper, 2015 · strength 0.07
  17. Hiroshi Y. Yamada · 1 shared paper, 2015 · strength 0.04
  18. Zobeida Cruz‐Monserrate · 1 shared paper, 2015 · strength 0.04
  19. Courtney W. Houchen · 1 shared paper, 2015 · strength 0.04
  20. James Randolph Sanders Hocker · 1 shared paper, 2013 · strength 0.04
  21. Jay S. Hanas · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.